Garda Therapeutics Bumps Assertio (ASRT) Tender Offer to $21.80/Share After Superior Proposal

The Deal in One Paragraph

Assertio Holdings, Inc. (NASDAQ: ASRT) has agreed to be taken private by Garda Therapeutics, Inc. through a cash tender offer at $21.80 per share, followed by a Section 251(h) back-end merger. The buying entity is Audi Merger Sub, Inc., a wholly owned subsidiary of Garda. The current price stands at $22.15, putting ASRT 1.6% above the offer — an unusual setup that signals the market expects either another bidder to surface or Garda to raise again. The tender offer is now expected to commence on or before May 8, 2026, per the preliminary SC14D9C filed May 5, 2026.

The Price Bump — What Actually Happened

The current $21.80 offer is not the original deal. On April 8, 2026, Assertio first announced an agreement with Garda at $18.00 per share in cash plus one non-tradeable contingent value right (CVR) tied to milestones on a legacy product called SPRIX. That valued ASRT's equity at roughly $125 million. The press release pegged the premium at 34.6% to the unaffected price on March 20, 2026, which implies an unaffected price of about $13.37.

Crucially, the original merger agreement included a 20-day "window-shop" period during which Assertio's board could solicit competing offers, with a reduced break fee ($1.75 million) if it terminated for a Superior Proposal. According to Assertio's May 4 announcement, the company "engaged with multiple parties" during the window-shop and received a Superior Proposal. Garda's response was to come back with a fully revised Amended and Restated Agreement and Plan of Merger dated May 1, 2026 that:

• Raises the cash price from $18.00 to $21.80 (+21.1%).
• Eliminates the CVR entirely — holders get straight cash, no contingent payments to chase.
• Implies a 63.1% premium to the same March 20, 2026 unaffected price.
• Lowers the minimum closing net cash threshold from $115 million to $95 million, reducing operational risk before close.
• Bumps the reciprocal termination fee from $4.8 million to $5.81 million.

The board has unanimously approved the amended deal. Whether a special committee was formed has not been disclosed in the preliminary SC14D9C; expect more detail in the definitive Schedule 14D-9 once the offer commences.

Why Is the Stock Trading Above the Offer?

A negative spread — the stock above the cash offer — is the single most interesting feature of this deal. ASRT closed at $22.15 against an offer of $21.80, and the 52-week high is $22.16. The stock is essentially pinned at the high.

There are three possible explanations, and only one is plausible here:

• Recent positive operating news. Unlikely. Assertio sold off most of its product portfolio (Indocin, Sprix, Sympazan, Cambia, Zipsor, Otrexup) to Cosette Pharmaceuticals for $35 million upfront as part of the original April 8 transaction structure. The company that Garda is buying is essentially a Rolvedon-only business. There is no fresh fundamental catalyst that re-rates ASRT past $21.80 on standalone merits.
• A known competing bid. Possible but not confirmed. The May 4 press release acknowledges a Superior Proposal during the window-shop, but that bidder has not been named publicly and there is no second public offer on the table.
• The market is paying for optionality on a second bump. This is the most credible read. Investors saw Garda match a Superior Proposal once already. They are wagering small that the same dynamic plays out again — either the Superior Proposer comes back over the top, or Garda has to raise to keep the deal closed. A 1.6% premium to the offer price is the price tag on that optionality.

Who Is Garda Therapeutics?

This is the biggest deal-certainty question for ASRT, because the buyer is not a household name. Garda Therapeutics is a Delaware-incorporated specialty pharma vehicle, not a strategic acquirer with a balance sheet, and not a brand-name private equity sponsor.

It is led by Joseph M. Limber and Brett K.E. Lund, both formerly of Secura Bio, a private specialty pharma operator. Limber is also the former CEO of Genoptix and Prometheus Laboratories. Garda's strategy, as described on its corporate site, is to acquire and operate mid-sized specialty pharmaceutical assets. The Assertio (Rolvedon) deal is its first publicly announced transaction.

The acquisition is funded by:

• Equity: $22.2 million from Limber and Lund personally (up from $17 million in the original deal).
• Debt: An $80 million senior secured term loan and a $50 million delayed-draw term loan facility from Colbeck Capital Management, a New York–based private credit firm — a meaningful step up from the original $87 million debt package.

Total committed financing is roughly $152 million, which lines up with the $151–152 million implied equity value at $21.80 per share. The merger agreement explicitly has no financing condition. That is not the same as money already in the bank, but lender financing commitments from a known direct-lending shop, paired with an equity backstop from the principals, materially de-risk closing.

Key Terms

Will This Deal Close?

The structural features point to a high probability of closing at $21.80, with the open question being whether someone else comes in over the top.

• Board approval: Unanimous on the amended deal. The board already faced a price discovery process via the window-shop period and chose Garda's revised bid over the alternative. That is meaningful diligence, not a rubber stamp.
• Financing: Equity commitments from the principals plus a sized-up Colbeck debt package, no financing condition. This is the strongest pillar of the deal.
• Minimum tender: A simple majority. With the board recommending and arb funds likely to participate, getting past 50% should not be hard for a deal trading above the offer.
• No-shop and matching rights: The window-shop has expired. Going forward, the agreement reverts to a customary no-shop with fiduciary out and matching rights. Any new interloper would have to make a clearly superior bid and Garda would get a window to match again.
• Regulatory: No HSR review has been disclosed and the deal's sub-$200M size sits well below mandatory filing thresholds. Antitrust risk is essentially nil.
• Probability of another competing bid: Real but not high. The Superior Proposer had its chance and either could not or chose not to top $21.80 and walk away from the break fee. Without a known second bidder making moves, the most likely path is closing at $21.80.

Timeline

Deal Structure (Plain English)

This is a two-step transaction. First, Audi Merger Sub launches a tender offer for all outstanding ASRT shares at $21.80 cash. If more than 50% of shares are tendered, Audi Merger Sub buys those shares and any remaining stockholders are cashed out at the same $21.80 in a back-end merger under Section 251(h) of Delaware corporate law. Section 251(h) lets the parties skip the usual stockholder vote because the tender already cleared a majority threshold — it is faster and simpler than a long-form merger. Whether you tender or not, you end up with $21.80 per share, but tendering speeds up the cash payment.

Risks

• Buying above the offer is its own risk. Anyone paying $22.15 today is locking in a $0.35 loss per share if the deal closes at $21.80 with no further bump. That is a roughly 1.6% downside that crystallizes within weeks. Optionality on a second bump is real but not free.
• Financing risk: low but not zero. No financing condition in the contract, but Garda still has to draw the Colbeck facilities at close. Colbeck is an established direct lender with committed paper here, but private credit can hit hiccups.
• Counterparty thinness. Garda Therapeutics is two principals plus debt. There is no large parent balance sheet to lean on if anything stresses. The reciprocal $5.81M break fee provides limited recourse if Garda walks.
• No odd-lot preference disclosed. Small holders cannot rely on an odd-lot bypass of proration; that said, since this is a 100% cash buyout, proration is not a relevant issue — every tendered share gets accepted.
• Regulatory and minimum tender risks: minimal. No HSR filing flagged, simple majority threshold, board-recommended deal.
• Competing bid that fails. If the original Superior Proposer comes back, gets matched again by Garda, and triggers another 20-day waiting cycle, the timeline drifts. Capital sits idle longer and the implied annualized return on any spread trade compresses.

The Bottom Line

This is a clean cash buyout that has already passed the most useful stress test: a real competing bid forced the price up 21% and produced a higher offer with no CVR strings attached. Existing ASRT holders have already been well served — sit, watch, and let the process play out. If a second bump arrives, the upside is captured automatically; if not, $21.80 in cash within weeks is a strong outcome from an unaffected price of roughly $13.37 just six weeks ago.

For new buyers, the calculus is harder. Paying $22.15 for a $21.80 deal is a directional bet that another bump is coming, and the evidence for that is thin. The Superior Proposer had its shot and seems to have stepped back. Unless you have a specific reason to think a known interloper is regrouping, this is not a sensible entry. Wait for the spread to flip positive or for a public announcement of a renewed competing bid.

For arbitrageurs, the cleanest expression of a "no second bump" view is a small short of the spread — short ASRT, collect the convergence to $21.80 on close. That is a low single-digit return for a few weeks of carry, with the obvious tail risk that a real second bidder shows up. Size accordingly.

This analysis is for informational purposes only and does not constitute investment advice. Read the complete filing and consult your own advisors before making any decisions.